×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

APAC Cancer Biological Therapy Market

ID: MRFR/Pharma/2980-HCR
50 Pages
Kinjoll Dey
October 2025

Asia Pacific Cancer Biological Therapy Market Research Report Information: By Type (Monoclonal Antibodies, Interferons, Interleukins, Cancer Growth Inhibitors, Gene Therapy, Colony-Stimulating Factors, Targeted Therapy, Cancer Vaccines and others), By Phases (Phase I, Phase II, Phase III) By End Users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

APAC Cancer Biological Therapy Market Infographic
Purchase Options

APAC Cancer Biological Therapy Market Summary

The Asia-Pacific Cancer Biological Therapy market is projected to grow significantly from 124.3 USD Billion in 2024 to 321.8 USD Billion by 2035.

Key Market Trends & Highlights

Asia Pacific Cancer Biological Therapy Key Trends and Highlights

  • The market is expected to experience a compound annual growth rate (CAGR) of 9.03 percent from 2025 to 2035.
  • By 2035, the market valuation is anticipated to reach 321.8 USD Billion, indicating robust growth potential.
  • In 2024, the market is valued at 124.3 USD Billion, reflecting a strong foundation for future expansion.
  • Growing adoption of innovative therapies due to increasing cancer prevalence is a major market driver.

Market Size & Forecast

2024 Market Size 124.3 (USD Billion)
2035 Market Size 321.8 (USD Billion)
CAGR (2025-2035) 9.03%

Major Players

Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India)

Key Companies in the APAC Cancer Biological Therapy Market market include

Market Segmentation

Intended Audience

  • Pharmaceutical Companies
  • Pharmaceutical Suppliers
  • Cancer Research Organizations
  • Potential Investors
  • Key Executive (CEO and COO) and Strategy Growth Manager
  • Research Companies

Asia Pacific Cancer Biological Therapy Market Key Players 

  • Merck & Co., Inc. (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Amgen Inc. (US)
  • Bristol-Myers Squibb (US)
  • Celgene (US)
  • Eli Lilly and Company (US)
  • EnGeneIC (Australia)
  • Pfizer (US)
  • Intas Pharmaceuticals Ltd. (India)
  • Sun Pharmaceutical Industries Ltd. (India)

Asia Pacific Cancer Biological Therapy Market Regional Analysis 

  • Pharmaceutical Companies
  • Pharmaceutical Suppliers
  • Cancer Research Organizations
  • Potential Investors
  • Key Executive (CEO and COO) and Strategy Growth Manager
  • Research Companies

Report Scope

Report Attribute/Metric Details
Market Size 2023 114.08 (USD Billion)
Market Size 2024 124.30 (USD Billion)
Market Size 2032 246.95 (USD Billion)
Compound Annual Growth Rate (CAGR) 9.23 % (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
Geographies Covered Asia Pacific
Key Vendors Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India)

Market Highlights

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

FAQs

What is the projected CAGR of the Asia Pacific Cancer Biological Therapy Market during the forecast period 2024-2032?

The projected CAGR of Asia Pacific Cancer Biological Therapy Market would 9.23% during the forecast period of 2024-2032.

What can hold back the Asia Pacific Cancer Biological Therapy Market growth?

The Asia Pacific Cancer Biological Therapy Market could be deterred by the high cost involved in the process.

Name the key players involved in the Asia Pacific Cancer Biological Therapy Market.

The players are F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Novartis AG (Switzerland), Amgen Inc. (US), Pfizer (US), Intas Pharmaceuticals Ltd. (India), Eli Lilly and Company (US), EnGeneIC (Australia), Celgene (US), and Sun Pharmaceutical Industries Ltd. (India).

What are the types involved in the Asia Pacific Cancer Biological Therapy Market?

Asia Pacific Cancer Biological Therapy Market segmented by types into interferon, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors, gene therapy, cancer vaccines, targeted therapy, and others.

What are the end-user segments discussed in the Asia Pacific Cancer Biological Therapy Market report?

Asia Pacific Cancer Biological Therapy Market segmented by end users into laboratories, cancer research centers, hospitals & clinics, and others.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions